Orthotopic homograft tumours (syngeneic) display distinct tumour infiltrate immune cell patterns from that of subcutaneous counterparts
Xiaolong Tu, Annie Xiaoyu An, Chen Jiang, Xinhe Feng, Houju Huang, and Henry Li
Subcutaneous homografts (e.g. syngeneic models) are the most commonly used preclinical immuno-oncology model for pharmacology studies. However, orthotopic tumours which grow in a more human disease-relevant environment, may be more biologically and pharmacologically appropriate models.
The tumour microenvironment (TME), including tumour infiltrating immune cells (TILs) may also be better maintained in orthotopic models, which can influence tumour biology and immunotherapy response.
This poster details the TIL analysis for subcutaneously and orthotopically implanted syngeneic and tumour homograft models, to assess any differences in TILs between the two transplantation types.
Read this Poster to Discover:
- That orthotopic homograft mouse tumours have distinct TIL patterns from subcutaneous tumours, which may contribute to different tumour biology and pharmacology
- That tumour infiltrating immune cells are significantly more infiltrated to the inside of orthotopic tumours compared with subcutaneous, for the pancreatic models studied here
- How anti-PD-1, anti-CTLA-4, or combination treatment results in further infiltration of TILs to the tumor centre in subcutaneous models